Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study.

    BMJ Open 2017 Aug 3;7(8):e017406. Epub 2017 Aug 3.
    Division of Psychiatry, University College London, London, UK.
    Objectives: To measure the incidence of movement side effects of antipsychotic drugs in adults with intellectual disability and compare rates with adults without intellectual disability.

    Design: Cohort study using data from The Health Improvement Network.

    Setting: UK primary care.

    Participants: Adults with intellectual disability prescribed antipsychotic drugs matched to a control group of adults without intellectual disability prescribed antipsychotic drugs.

    Outcome Measures: New records of movement side effect including acute dystonias, akathisia, parkinsonism, tardive dyskinaesia and neuroleptic malignant syndrome.

    Results: 9013 adults with intellectual disability and a control cohort of 34 242 adults without intellectual disability together contributed 148 709 person-years data. The overall incidence of recorded movement side effects was 275 per 10 000 person-years (95% CI 256 to 296) in the intellectual disability group and 248 per 10 000 person-years (95% CI 237 to 260) in the control group. The incidence of any recorded movement side effect was significantly greater in people with intellectual disability compared with those without (incidence rate ratio 1.30, 95% CI 1.18 to 1.42, p<0.001, after adjustment for potential confounders), with parkinsonism and akathisia showing the greatest difference between the groups. Neuroleptic malignant syndrome, although occurring infrequently, was three times more common in people with intellectual disability-prescribed antipsychotic drugs (incidence rate ratio 3.03, 95% CI 1.26 to 7.30, p=0.013). Differences in rates of movement side effects between the groups were not due to differences in the proportions prescribed first and second-generation antipsychotic drugs.

    Conclusions: This study provides evidence to substantiate the long-held assumption that people with intellectual disability are more susceptible to movement side effects of antipsychotic drugs. Assessment for movement side effects should be integral to antipsychotic drug monitoring in people with intellectual disability. Regular medication review is essential to ensure optimal prescribing in this group.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
    Source Status
    http://dx.doi.org/10.1136/bmjopen-2017-017406DOI ListingPossible
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724123PMCFound

    Similar Publications

    Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.
    BMJ 2015 Sep 1;351:h4326. Epub 2015 Sep 1.
    Research Department of Primary Care and Population Health, University College London (Royal Free Campus), London NW3 2PF, UK.
    Objectives: To describe the incidence of recorded mental illness and challenging behaviour in people with intellectual disability in UK primary care and to explore the prescription of psychotropic drugs in this group.

    Design: Cohort study.

    Setting: 571 general practices contributing data to The Health Improvement Network clinical database. Read More
    Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice.
    BMJ Open 2016 12 5;6(12):e013116. Epub 2016 Dec 5.
    Imperial College, London, UK.
    Objectives: To determine the prevalence and quality of antipsychotic prescribing for people with intellectual disability (ID).

    Design: A clinical audit of prescribing practice in the context of a quality improvement programme. Practice standards for audit were derived from relevant, evidence-based guidelines, including NICE. Read More
    Sertindole for schizophrenia.
    Cochrane Database Syst Rev 2005 Jul 20(3):CD001715. Epub 2005 Jul 20.
    Department of General Practice, North Wales Clinical School, Cardiff University, Gwenfro Unit 5, Wrexham Technology Park, Wrexham, UK, LL13 7YP.
    Background: Sertindole is an atypical antipsychotic, which is thought to give a lower incidence of extrapyramidal side effects at clinically effective doses than typical antipsychotic drugs. In December 1998, Lundbeck Ltd., the manufacturers of sertindole, voluntarily suspended the availability of the drug due to concerns about cardiac arrhythmia and sudden cardiac death associated with its use. Read More
    Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID).
    Health Technol Assess 2009 Apr;13(21):iii-iv, ix-xi, 1-54
    Department of Psychological Medicine, Imperial College, London, UK.
    Objective(s): To assess the effects and cost-effectiveness of haloperidol, risperidone and placebo on aggressive challenging behaviour in adults with intellectual disability.

    Design: A double-blind randomised controlled trial of two drugs and placebo administered in flexible dosage, with full, independent assessments of aggressive and aberrant behaviour, global improvement, carer burden, quality of life and adverse drug effects at baseline, 4, 12 and 26 weeks, and comparison of total care costs in the 6 months before and after randomisation. At 12 weeks, patients were given the option of leaving the trial or continuing until 26 weeks. Read More